TY - JOUR AU - Campbell-Silva, S. E. AU - de la Cruz-Esparza, L. AU - Vásquez-Arias, F. PY - 2021/03/19 Y2 - 2024/03/29 TI - Bullous pemphigoid associated with vildagliptin JF - Revista Colombiana de Endocrinología, Diabetes & Metabolismo JA - Rev.ACE VL - 7 IS - 3 SE - Clinical Cases DO - 10.53853/encr.7.3.631 UR - https://revistaendocrino.org/index.php/rcedm/article/view/631 SP - 182-186 AB - <p>The prevalence of type 2 diabetes mellitus continues to increase steadily as more people live longer, and dipeptidyl peptidase-IV inhibitors, oral medications with no risk of hypoglycemia and neutral with respect to weight, become a therapeutic option for this group of elderly. However, dipeptidyl peptidase-4 inhibitors have been associated with severe skin reactions including bullous pemphigoid, and due to the morbidity and mortality associated with this condition, it is necessary to sensitize health professionals to know this link and be alert to any adverse skin reaction of these medications in at risk populations. We present two cases of bullous pemphigoid associated with vildagliptin.</p> ER -